Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Cybin Inc (CYBN)

Cybin Inc (CYBN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 314,341
  • Shares Outstanding, K 160,378
  • Annual Sales, $ 650 K
  • Annual Income, $ -24,420 K
  • 60-Month Beta N/A
  • Price/Sales 465.61
  • Price/Cash Flow N/A
  • Price/Book 4.75
Trade CYBN with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.21
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/12/21
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    SIC-6770 Blank Checks

    Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.07
  • Number of Estimates 3
  • High Estimate -0.07
  • Low Estimate -0.07
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.01%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.8600 +5.38%
on 10/22/21
2.4300 -19.34%
on 09/24/21
-0.1700 (-7.98%)
since 09/22/21
3-Month
1.6800 +16.67%
on 08/19/21
3.3800 -42.01%
on 08/02/21
-1.0100 (-34.01%)
since 07/22/21

Most Recent Stories

More News
Magic Mushrooms Could Be the Biggest Advance for Depression, Says Newsweek

“Magic mushrooms may be the biggest advance in treating depression since Prozac,” says Newsweek. ...

CYBN : 1.9600 (-1.01%)
FTRP.TO : 6.91 (+0.14%)
NUMI.VN : 0.700 (-4.11%)
LKYSF : 0.5660 (-4.07%)
MNMD : 2.43 (-2.02%)
FTRP : 5.65 (+0.53%)
CMPS : 38.89 (+10.14%)
Cybin Announces Completion of 74 Pre-Clinical Psychedelic Molecule Studies

Cybin Inc. ( NEO:CYBN ) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing psychedelic therapeutics, today announced the completion of its 74 th...

CYBN.NE : 2.380 (-2.46%)
CYBN : 1.9600 (-1.01%)
Strong Pipeline of Drugs for Treatment Of Psychotic Disorders Anticipated To Drive The Market Through 2028

/PRNewswire/ -- There is a high demand for more advanced products for the treatment and maintenance of severe mental disorders. Thus, pharmaceutical companies...

KTTA : 2.69 (+0.75%)
CMPS : 38.89 (+10.14%)
FTRP : 5.65 (+0.53%)
CYBN : 1.9600 (-1.01%)
ATAI : 15.25 (+0.53%)
Cybin Announces Additional Adelia Milestone Achievements

Cybin Inc. ( NEO:CYBN ) (NYSE AMERICAN:CYBN) (“ Cybin ” or the “ Company ”), a biotechnology company focused on psychedelic pharmaceutical therapies, is pleased to announce that Adelia Therapeutics...

CYBN.NE : 2.380 (-2.46%)
CYBN : 1.9600 (-1.01%)
Psychedelics Could Alter a Potential $2.5 Trillion Mental Health Market

Psychedelics could soon revolutionize the $2.5 trillion mental health market. In fact, according to ...

CYBN : 1.9600 (-1.01%)
CLXPF : 3.0200 (-1.31%)
FTRP.TO : 6.91 (+0.14%)
FTRP : 5.65 (+0.53%)
MCURF : 0.2425 (-2.22%)
ATAI : 15.25 (+0.53%)
NMDBF : 0.0682 (-5.54%)
FTRP.CN : 5.550 (+1.46%)
MCUR.CN : 0.300 (-3.23%)
NEON.CN : 0.090 (unch)
The AdvisorShares Psychedelics ETF Officially Hits the Market

On Sept. 16, the AdvisorShares Psychedelics ETF (NYSE Arca: PSIL) began trading. Its monumental because ...

PSIL : 9.20 (+0.45%)
CYBN : 1.9600 (-1.01%)
FTRP : 5.65 (+0.53%)
MNMD : 2.43 (-2.02%)
CMPS : 38.89 (+10.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Cybin Inc. is a biotechnology company. It is focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. Cybin Inc. is based in Toronto, Canada.

See More

Key Turning Points

3rd Resistance Point 2.1267
2nd Resistance Point 2.0533
1st Resistance Point 2.0067
Last Price 1.9600
1st Support Level 1.8867
2nd Support Level 1.8133
3rd Support Level 1.7667

See More

52-Week High 3.3800
Fibonacci 61.8% 2.2775
Last Price 1.9600
Fibonacci 50% 1.9369
Fibonacci 38.2% 1.5963
52-Week Low 0.4938

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar